Newspaper article The Canadian Press


Newspaper article The Canadian Press


Article excerpt



U-S regulators have approved a new drug that harnesses the immune system to treat bladder cancer that has spread after chemotherapy or surgery.

The Food and Drug Administration approved Imfinzi for advanced bladder cancer, along with a companion test for identifying which patients are most likely to benefit from it.

Imfinzi, also known as Durvalumab, is part of a new generation of drugs that stimulate the immune system to help fight cancer.

Imfinizi works by binding to a protein, found in varying levels on tumour cells, that blocks immune system cells from attacking the tumour.

British drugmaker AstraZeneca P-L-C, which developed the drug, is testing it for several other cancers. (The Associated Press)



A study on bullying prevalence among schools in the state of Maryland suggests it may finally be on the decline.

Researchers at Johns Hopkins University conducted a large study spanning 10 years, looking at 109 schools and more than 246-thousand students.

The study was published in the journal Pediatrics.

During the study period, bullying behaviours decreased by 33 per cent overall, while students reported witnessing bullying 50 per cent less often, and were 35 per cent less likely to identify as a bully themselves.

Despite concerns that cyber-bullying would increase, it remained low, with fewer than 10 per cent of kids reporting an experience with it. (ABC)



A new study has found diet patterns before the age of three have a tremendous influence on health, and what you will consider tasty and gravitate toward for the rest of your life.

In the study published in the journal Pediatrics, researchers compared the diets of infants and toddlers in 2005-2008 to those in 2009-2012.

While there have been some improvements, far too few kids between six-and-23 months are still eating the recommended amount of vegetables. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed


An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.